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Enhanced DNA damage repair is one mechanism involved in colon cancer drug
resistance. Thus, targeting molecular components of repair pathways with specific small
molecule inhibitors may improve the efficacy of chemotherapy. ABT-888 and VE-821,
inhibitors of poly-ADP-ribose-polymerase (PARP) and the serine/threonine-kinase Ataxia
telangiectasia related (ATR), respectively, were used to treat colon cancer cell lines in
combination with the topoisomerase-I inhibitor irinotecan (SN38). Our findings show that
each of these DNA repair inhibitors utilized alone at nontoxic single agent concentrations
resulted in sensitization to SN38 producing a 1.4–3 fold reduction in the 50% inhibitory
concentration (IC50) of SN38 in three colon cancer cell lines. When combined together,
nontoxic concentrations of ABT-888 and VE-821 produced a 4.5–27 fold reduction in the
IC50 of SN38with the HCT-116 colon cancer cells demonstrating the highest sensitization
as compared to LoVo and HT-29 colon cancer cells. Furthermore, the combination of all
three agents was associated with maximal G2 −M arrest and enhanced DNA-damage
(γH2AX) in all three colon cancer cell lines. The mechanism of this enhanced sensitization
was associated with: (a) maximal suppression of SN38 induced PARP activity in the
presence of both inhibitors and (b) ABT-888 producing partial abrogation of the VE-821
enhancement of SN38 induced DNA-PK phosphorylation, resulting in more unrepaired
DNA damage; these alterations were only present in the HCT-116 cells which have
reduced levels of ATM. This novel combination of DNA repair inhibitors may be useful
to enhance the activity of DNA damaging chemotherapies such as irinotecan and help
produce sensitization to this drug in colon cancer.
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Introduction
DNA-interacting chemotherapy drugs remain the mainstay therapy for most advanced cancers,
including metastatic colon cancer. The introduction of irinotecan and oxaliplatin has doubled
survival of patients with metastatic colon cancer, but still the majority of patients with this disease
die within 3 years of diagnosis of metastases (Goldberg et al., 2004). Reports by us and others
demonstrating that DNA repair is an important factor in resistance to chemotherapy have lent
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support to the development of inhibitors of key enzymes
involved in the DNA damage response (DDR) with promising
preclinical results (Panasci et al., 2001; Aloyz et al., 2004;
Willmore et al., 2004; Amrein et al., 2011; Siddiqui-Jain et al.,
2012; Davidson et al., 2012a). At the apex of the DDR are
three related protein kinases: Ataxia telangiectasia mutated
(ATM), Ataxia-telangiectasia-and-Rad3-related (ATR) and
DNA-dependent protein kinase (DNA-PK). These kinases
belong to the phosphoinositide-3-kinase-related protein
kinase family and share structural homologies and modes
of regulation (Mordes and Cortez, 2008; Lempiainen and
Halazonetis, 2009; Lovejoy and Cortez, 2009). Whereas, all
three kinases are activated by DNA double-strand breaks
(DSBs), ATR can also be activated by base adducts and
cross-links in the DNA. Furthermore, Poly ADP ribose
polymerase 1 (PARP1), which catalyzes the formation
of poly ADP ribose chains (PAR) on cellular DNA and
proteins, is rapidly recruited to and activated by DSBs and
DNA nicks. The addition of PAR by PARP1 can alter the
functions of modified proteins such as topoisomerase-I and
DNA-PK. Inhibitors of DNA-PK or PARP individually can
sensitize cancer cells to DNA-damaging agents (Willmore
et al., 2004; Donawho et al., 2007; Penning et al., 2009;
Amrein et al., 2011; Siddiqui-Jain et al., 2012; Davidson
et al., 2012b). We have previously demonstrated increased
sensitization of primary chronic lymphocytic leukemia cells
to chlorambucil by the use of two DNA repair inhibitors
employed together targeting HRR and/or DNA-PK (Amrein
et al., 2011).
As cancer cells deficient in ATR or DSB repair are sensitive
to inhibitors of PARP1 (Audeh et al., 2010; Tutt et al., 2010;
Huehls et al., 2012), we hypothesized that inhibition of ATR and
PARP1 would result in more sensitization to the DSB inducing
agent, irinotecan. Noteworthy, irinotecan induces cell cycle arrest
in an ATR-dependent manner through Chk1 phosphorylation,
an accepted marker of ATR activity (Zhao and Piwnica-Worms,
2001; Nam and Cortez, 2011). Also, our reported results showing
that an inhibitor of PARP1 (ABT-888) sensitizes colon cancer
cell lines to irinotecan (Davidson et al., 2013) have lead to an
ongoing clinical trial (clicaltrials.gov, Abbvie, NCT02305758).
ATR is involved in many biological processes including DDR and
replication stress. Inhibitors of ATR are in development (Fokas
et al., 2014). One of these, VE-821 has resulted in sensitization of
human cancer cell lines to many chemotherapies (Reaper et al.,
2011). Additionally, it has been reported (Reaper et al., 2011;
Ahmed et al., 2013) that the ATR inhibitor VE-822 improved the
efficacy of gemcitabine and radiation in treatment of pancreatic
cancer cells while not affecting normal cells both in-vitro and
in-vivo. The reports of the potent sensitizing effect of ATR
inhibitors, including VE-821, on chemotherapy (Reaper et al.,
2011) prompted us to assess the effect of the combination of
ABT-888 and VE-821, targeting PARP and ATR, respectively, on
irinotecan cytotoxicity in colon cancer cells. For this purpose
we utilized the micro-satellite-instability, p53, BRAF and PTEN
wild-type HCT-116 and LoVo colon cancer cell lines plus the p53
mutated micro-satellite-stable, BRAF mutated, PTEN wild type
HT-29 cell line (Ahmed et al., 2013).
Materials and Methods
Cell Lines, Drug Treatments, and Reagents
The genetically diverse colon cancer cell lines HCT-116, HT-
29, and LoVo were obtained from the American Type Culture
Collection (ATCC) and maintained as monolayers at 37◦C
in 5% CO2 in RPMI, McCoy’s, or Ham’s F-12 medium,
respectively, supplemented with 10% fetal bovine serum and
penicillin/streptomycin. All experiments were performed on cells
in exponential growth phase.
SN38 (the activated form of irinotecan), chemicals and
reagents were obtained from Sigma-Aldrich or Invitrogen.
Abbott Laboratories provided ABT-888, and VE-821 was
generously donated by Vertex pharmaceutical (Abingdon,
Oxfordshire, UK).
Sulforhodamine (SRB) Cytotoxicity Assay
SRB assays were performed as described by us and by Vichai
et al. (Vichai and Kirtikara, 2006; Davidson et al., 2012a). It has
been previously shown that cytotoxicity results obtained with
the SRB assay correlate well with both the MTT and clonogenic
assays. Furthermore, this assay has been adopted by the NCI
for large scale screening of new drugs (Perez et al., 1993). Cells
were treated with SN38, the PARP inhibitor ABT-888, and the
ATR inhibitor VE-821 alone or in combination (concentrations
indicated in results section). Five days after drug treatment,
the percentage of surviving cells was measured using a 96-well
plate reader. Plating efficiency experiments were performed to
determine the ideal plating density and ensure cells were growing
exponentially at the 5 day time point. The 5-day time point
was selected to permit approximately 4 growth cycles before
fixing cells. The efficacy of the various drug treatments was
determined by calculating the 50% inhibitory concentrations
(IC50) and sensitization values. Sensitization values (R-values)
were calculated using the equation described by Willmore
et al. (2008). According to this equation, values greater than
1 indicate sensitization. Each experiment consisted of triplicate
drug treatments, and experiments were repeated at least three
times. Wells treated with DMSO (vehicle), ABT-888 alone, VE-
821 alone or VE-821/ABT-888 (without SN38) were used as
controls in all experiments.
Cell Cycle Analysis
Cells were grown on 6-well tissue culture plates, incubated
with each drug separately (concentrations indicated in figure
legends) or with drug combinations for 24 h (exponential
growth), trypsinized, fixed, and permeabilized with 75% ethanol
in Ca2+/Mg2+ free PBS, and stored at −20◦C. Cells were
stained with 5µg/mL 7-amino-actinomycin D (7AAD) or
propidium iodide (PI), treated with 0.2mg/mL RNAseA as
per our laboratory protocol and examined by flow cytometry
(Davidson et al., 2012a). A minimum of 20,000 events was
recorded for each sample.
Quantification Of The Double Stranded DNA
(dsDNA) Damage Marker γH2AX
Cells were prepared as described for cell cycle analysis, incubated
with mouse anti-γH2AX antibodies at 4◦C overnight, and
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washed with phosphate-buffered saline (PBS). Cells were then
incubated with goat anti-mouse Alexa 488-conjugated secondary
antibodies for 1 h and washed in PBS. The mean fluorescence
intensity was measured to determine levels of γH2AX at 24 h
post-treatment as described (Davidson et al., 2013).
Western Blotting
HCT-116 cells were grown in T25 flasks for 24 h (exponential
growth), treated with anti cancer drugs (as indicated in figure
legends) and harvested by scraping 24 h post treatment. Cells
were centrifuged at 1500 rpm for 5min and pellets washed in cold
PBS. Pellets were dissolved in lysis buffer as previously described
(Davidson et al., 2012b, 2013). Cell lysates were separated by
SDS-PAGE, transferred to nitrocellulose membranes under the
appropriate conditions, and blotted for the following antigens:
total Chk1 (Santa Cruz, sc-8408), DNA-PK (Upstate, 05-423)
and Rad51 (Upstate), phosphorylated antibodies; Chk1 (S317)
(Cell Signaling, 2344), DNA-PK (S2056) (Abcam, ab18192) and
Rad51 (T309) (Abcam) and β-actin (Santa Cruz, sc-1616). Chk1,
DNA-PK and Rad51 levels were normalized to β-actin and
phosphorylated-Chk1, -DNA-PK, and -Rad51 were normalized
to total-Chk1, total-DNA-PK and total-Rad51 respectively. Each
experiment was repeated at least 3 times. Blots were quantified
using ImageJ image analysis software.
PARP Inhibition Assay
T25 flasks were inoculated with 5×105 HCT-116 cells and grown
for 24 h as previously described (Davidson et al., 2013). Cells
were treated with the PARP inhibitor ABT-888, VE-821, or SN38
alone or in combination for 24 h (concentrations indicated in
figure legend). Cells were harvested by scraping, centrifuging
at 1500 rpm for 5min and lysed in 25µL of lysis buffer. The
resulting supernatant was assayed for PARP activity using the
Trevigen Inc. universal PARP assay as previously done (Davidson
et al., 2013). All activity measurements were normalized to total
PARP protein levels as determined by western blot analysis.
Statistical Analysis
Data analysis was performed using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Statistically significant changes
were determined using two-tailed unpaired Student’s t-tests.
Results
The Combination of Non-Cytotoxic
Concentrations of VE-821 plus ABT-888 Had a
Greater Effect on Sn38 Cytotoxicity than Either
Inhibitor Alone
The IC50 of SN38 alone was measured separately in the
colon cancer cell lines HCT-116, HT-29 and LoVo (Figure 1,
Supplemental Table 1). The HCT-116 cell line was the most
sensitive to SN38 while the HT-29 cell line was the most resistant.
Additionally, ABT-888 and VE-821 were tested individually
in each cell line to obtain the corresponding IC50 values
(Supplemental Table 2). Again, the HCT-116 cells were the
most sensitive to ABT-888 and HT-29 cells were the most
resistant to ABT-888 (38–100µM). Moreover, HT-29 cells were
10 fold more resistant and LoVo cells were 6 fold more resistant
to VE-821 as compared to HCT-116 cells (10.5–100µM).
Based on the IC50 values obtained for ABT-888 and VE-821
non-toxic concentrations of these compounds were selected
for combination drug treatments with SN38. At the selected
concentrations [VE-821 alone (0.5 or 1µM), ABT-888 alone
(0.5µM), and VE-821 (0.5 or 1µM) plus ABT-888 (0.5µM)],
there was no evidence of decreased cell growth and/or increased
death. Our previous study demonstrated that 0.5µM ABT-888
optimally sensitized colon cancer cell lines to SN38 (Davidson
et al., 2013). Combining 0.5µMABT-888 with SN38 reduced the
SN38 IC50 in all tested cell lines with the greatest sensitization
observed in the HCT-116 cell line (1.4–2.1 fold sensitization).
Furthermore, the IC50 of SN38 was reduced significantly by the
addition of VE-821 at 0.5 or 1µM in all cell lines (1.6–3 fold
sensitization). The observed effect was dose-dependent with the
higher concentration of VE-821 modestly decreasing the IC50 of
SN38 (Figure 1, Supplemental Table 1). The combination of both
inhibitors at non-toxic concentrations resulted in the greatest
decrease in SN38 IC50 values (HCT-116: 27 fold, LoVo and
HT-29: 4.5 and 5.3 fold) (Figure 1, Supplemental Table 1).
The Sensitization Effect of VE-821 plus ABT-888
on SN38 Cytotoxicity Was Associated With
Promotion of G2-M Cell Cycle Arrest and
Increased γH2AX Levels
HCT-116, HT-29, and LoVo cells treated with SN38 for 24 h
accumulated in the S and G2-M phases of the cell cycle
(Figures 2A–C). In HCT-116 and HT-29 cells, the combination
treatment with ABT-888 plus VE-821 and SN38 had the
greatest increase in G2-M arrest as compared with SN38 alone
(Figures 2A,B). In LoVo cells there was less effect on G2-M
arrest (Figure 2C). These results are consistent with our previous
publication on ABT-888 with irinotecan and the results of
Reaper et al., showing the effects of VE-821 plus chemotherapy
(Davidson et al., 2013; Reaper et al., 2011).
Histone H2AX is phosphorylated on Ser139 (γH2AX) in the
presence of DSBs, and is therefore used as a surrogate marker
of DSBs (Paull et al., 2000). Our data show that treatment with
the combination ABT888/VE-821, SN38 alone or the different
combinations of these inhibitors with SN38, increased γH2AX
levels in the 3 colon cancer cell lines. The highest level of γH2AX
was observed in the SN38/ABT-888/VE-821 combination-treated
cells (Figure 3).
ABT-888 Abrogated Basal and Drug-Induced
PARP Activity in Colon Cancer Cells
The 3 colon cancer cell lines were treated with SN38, ABT-888
and/or VE-821 alone or various combinations of the three drugs
for 24 h and assayed for PARP enzymatic activity (Figure 4).
64nM SN38 significantly increased PARP activity in these cells.
ABT-888 dramatically reduced PARP activity in the presence
and absence of SN38 in a dose-dependent fashion. Treatment
with VE-821 alone was also associated with increased PARP
activity in HCT-116 and LoVo cell lines. In contrast, cells treated
with SN38 combined with VE-821 had lower levels of PARP
activity than cells treated with SN38 alone in HCT-116 cells and
to a lesser extent in LoVo cells (p ≤ 0.05) but not in HT-
29 cells. Moreover, HCT-116 cells treated with combinations of
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FIGURE 1 | Cytotoxicity curves plotting cell density of drug
treated samples relative to the vehicle-treated control for 3
colon cancer cell lines. (A) HCT-116 combinations including
0.5µM VE-821, (B) HCT-116 combinations including 1.0µM
VE-821, (C) HT-29 combinations including 0.5µM VE-821, (D)
HT-29 combinations including 1.0µM VE-821, (E) LoVo
combinations including 0.5µM VE-821, and (F) LoVo combinations
including 1µM VE-821.
SN38/ABT-888/VE-821 had the lowest levels of PARP activity
compared to cells treated with SN38 combined with ABT-888
(p ≤ 0.05) (Figure 4A), while this was not seen with the other
two cell lines (Figures 4B,C).
VE-821 and/or ABT-888 Decreased SN38 Induced
Chk1 Phosphorylation
Exposing HCT-116 cells to increasing concentrations of VE821
(0.25–16µM) combined with 64nM SN38 caused a progressive
reduction in Chk1 phosphorylation (Ser317) plateauing at 1µM.
The effect of the combination treatment of PARP and ATR
inhibitors plus SN38 was assessed by western blotting samples in
the HCT-116 cell line (Figure 5). While ABT-888 in combination
with SN38 demonstrated a reduction in phosphorylation of
Chk1, VE-821 at 1–2µM largely suppressed SN38–induced Chk1
phosphorylation as previously described (Fokas et al., 2014)
(Figure 5). The addition of ABT-888 had no further effect on
VE-821 suppression of SN38-induced Chk1 phosphorylation
(Figure 5).
pDNA-PK is Increased in Response to ATR
Inhibition in a PARP Dependent Manner
In addition to p-Chk1, western blot analysis was also done
for pRAD51 and p-DNA-PK to determine the effects of
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FIGURE 2 | Cell cycle analysis of (A) HCT-116, (B) HT-29, and (C) LoVo
cell lines 24h post treatment with IC50 concentrations of SN38 (S)
and/or 0.5µM ABT-888 (A) 1µM VE-821 (V) or both (AV). (NT) cells
treated with vehicle alone, (AV) ABT-888 and VE-821, (SA) SN38 and
ABT-888, (SV) SN38 and VE-821, and (SAV) SN38, ABT-888 and VE-821 in
combination.
SN38, ABT-888, and VE-821 treatment on HRR and NHEJ,
respectively (Figure 6). p-RAD51 protein levels increased with
SN38 treatment in a dose dependent manner but did not change
with addition of either ABT-888 or VE-821 (Supplemental
Figure 1).
The levels of p-DNA-PK increased incrementally with
the SN38 concentration. SN38 (64 nM) combined with 1
or 2µM VE-821 caused a substantial increase in DNA-PK
phosphorylation compared to SN38 alone in all 3 cell lines
(Figures 6A,B) This response was diminished by the addition
of 0.5µM ABT-888 to the SN38/VE-821 combinations only in
HCT-116 cells (Figures 6A,B).
Discussion
Improvements in understanding of DNA repair pathways and
their relationships has facilitated the development of several
targeted therapies aimed at sensitizing neoplastic cells to the
effect of DNA-damaging chemotherapy (Reaper et al., 2011).
As such, the ATR-Chk1 pathway is a potential target for anti-
cancer therapy and ATR-selective inhibitors are currently in
development. These inhibitors hold significant potential because
the ATR-Chk1 pathway plays important roles in regulating cell
cycle arrest, NHEJ, and HRR (Fokas et al., 2014; Chen et al.,
2012).
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FIGURE 3 | Flow cytometric analysis of γH2AX in (A) HCT-116, (B)
HT29, and (C) LoVo colon cancer cells 24 h-post treatment with
SN38 at IC50 concentrations (s) (solid black line) and/or 0.5µM
ABT-888 (a) and/or 1µM VE-821 (v) drug combinations [dashed
black lines. n = cells treated with vehicle alone (solid gray
area)].
Our results revealed that a combination of both a PARP and an
ATR inhibitor at non-toxic concentrations plus SN38 produced
a dramatic 4.5–27-fold decrease in the IC50 of SN38 across the
various cell lines with the largest decrease occurring in HCT-
116 cells. The addition of each inhibitor separately to SN38
enhanced its cytotoxic effect, but to a lesser extent than when
cells were treated with all three drugs. 0.5µMABT-888 was used
in this work because in a previous study, higher concentrations
(1–4µM) did not provide additional sensitization to SN38
(Davidson et al., 2013). In agreement with the cytotoxicity results,
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FIGURE 4 | PARP-activity in colon cancer cell lines as percent of
untreated control cells. (A) HCT-116 cells, (B) HT-29 cells, and (C) LoVo
cells. Cells treated with vehicle alone (N), 0.5µM ABT-888 (0.5A), 0.5µM
VE-821 (0.5V) or 1µM VE-821 (1V), 64 nM SN38 (S) alone or in combination
with varying concentrations of ABT-888 (A 0.125–0.5µM), cells treated with
64 nM SN38 in combination with 0.5µM VE-821 (S.5V) and varying
concentrations of ABT-888 (0.125–0.5µM) and cells treated with 64 nM SN38
in combination with 1µM VE-821 (S1V) and varying concentrations of
ABT-888 (0.125–0.5µM). *Significantly different from untreated control,
γsignificantly different from cells treated with SN38 alone. p ≤ 0.05.
G2-M arrest was most significant in cells treated with all three
drugs.
In addition to cell cycle arrest, combination drug treatments
also increased DNA damage (DSBs) as indicated by increased
levels of γH2AX, which is an indicator of DNA double strand
breaks (Paull et al., 2000). The highest levels of γH2AX were
observed in response to combination treatment with all three
drugs, most likely due to decreased DNA repair capacity in the
presence of the inhibitors.
VE-821 stimulated PARP activity in the HCT-116 and LoVo
cell lines is possibly secondary to unresolved replication stress
due to the absence of ATR activity. This was not observed in
the HT-29 cells and may be related the fact that they are p53
mutated with altered replication stress signaling. As expected
the PARP inhibitor ABT-888 decreased PARP activity both in
the absence and presence of SN38. The two inhibitors together
decreasedmaximally the PARP activity only in theHCT-116 cells.
This may be secondary to decreased ATM levels in HCT-116 cells
since depletion of ATM in breast cancer cells confers sensitivity
to PARP inhibition (Gilardini et al., 2013).
FIGURE 5 | Effect of combination drug treatments (24 h) on the
expression and phosphorylation status of Chk-1 (S317) in HCT-116
cells as determined by western blot analysis, representative of 3
replicates. NT = vehicle treated control, S8 = 8 nM SN38, S32 = 32 nM
SN38, S64 = 64 nM SN38, A0.5 = 0.5µM ABT-888, V1 = 1µM VE-821, and
V2 = 2µM VE-821. *Significantly different from NT cells, εsignificantly different
from S64 cells, p ≤ 0.05.
Interestingly, SN38 induced autophosphorylation of DNA-
PK was increased in all three cell lines in the presence of the
ATR inhibitor VE-821. The increase in pDNA-PK is likely a
mechanism to compensate for the lack of ATR activity at stalled
replication forks in the presence of SN38. We speculate that
reduced ATR activity in the presence of the ATR inhibitor
prevented repair of DNA damage resulting from SN38 activity
leading to the formation of DSBs and increased recruitment
and autophosphorylation of DNA-PK. This autophosphorylation
of DNA-PK was diminished when ABT-888 was used in
combination with SN38 and VE-821 only in the HCT-116 cells.
Interaction of DNA-PK and PARP has been shown to cause
substantial conformational changes in the DNA-PK synaptic
dimer (Spagnolo et al., 2012). Furthermore, DNA-PK is ADP-
ribosylated by PARP which stimulates the activity of DNA-PK
(Ruscetti et al., 1998). HCT-116 cells have decreased levels of
ATM as compared to the two other cell lines (Kim et al., 2002;
Zhou et al., 2014). Also in the presence of an ATM inhibitor
induction of DSBs in human cells decreased autophosphorylation
of DNA-PK (Zhou and Paull, 2013). This suggests that the
decrease in phospho-DNA-PK seen in the presence of two
inhibitors together with SN38 only in the HCT-116 cells may be
related to the decreased levels of ATM in these cells.
As such, the observed sensitization effect of both inhibitors
utilized with SN38 in the colon cancer cell lines may be related
to the combined inhibition of both pathways. Since PARP-1 and
ATR co-immunoprecipitated in extracts prepared from MMS-
treated cells implying a potential direct interaction between these
pathways (Kedar et al., 2008) this interaction may be altered in
the presence of these inhibitors in the presence of SN-38 such
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FIGURE 6 | Effect of combination drug treatments (24 h) on the
expression and phosphorylation status of DNA-PK (S2056) in 3
colon cancer cell lines as determined by western blot analysis,
representative of 3 replicates. (A) HCT-116 cells treated with:
NT = vehicle treated control, S8 = 8 nM SN38, S32 = 32 nM SN38,
S64 = 64 nM SN38, A0.5 = .5µM ABT-888, V1 = 1µM VE-821, and
V2 = 2µM VE-821. (B) HT-29 (black bars) and LoVo (white bars) cells
treated with S64 = 64 nM SN38, A0.5 = 0.5µM ABT-888, V1 =
1µM VE-821 alone or in combinations as indicated. *Significantly
different from NT cells, εsignificantly different from S64 cells,
θsignificantly different from cells treated with SN38 and corresponding
levels of VE-821, p ≤ 0.05.
that there is more sensitization. This effect is optimal in the HCT-
116 cells as a result of both optimal suppression of PARP activity
and attenuation of DNA-PK activation possibly due to decreased
ATM levels. Interestingly, a recent clinical study associated low
ATM expression in colon cancer with poor clinical outcomes
(Beggs et al., 2012). Our data suggests that the combination
of ABT-888, VE-821, and SN38 may improve chemotherapy in
these patients.
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Conclusion
Chemotherapy remains the mainstay of cancer treatment.
Treatment strategies to enhance cytotoxicity or minimize adverse
events have emerged and are being developed. Among small
molecule inhibitors used to improve the therapeutic index, ABT-
888, a PARP inhibitor, and VE-821, a selective ATR inhibitor,
were examined. Combination treatment with these inhibitors
at nontoxic concentrations with SN38 resulted in the greatest
chemosensitization along with increased DNA damage. The
present data suggest that this combination may effectively
sensitize some colon cancers to irinotecan-based chemotherapy.
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